Literature DB >> 23002379

Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review.

.   

Abstract

Entities:  

Year:  2012        PMID： 23002379      PMCID： PMC3442617     

Source DB:  PubMed          Journal:  CADTH Technol Overv        ISSN： 1203-9012


× No keyword cloud information.
  31 in total

1.  Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.

Authors:  W Wolfgang Fleischhacker; Martti E Heikkinen; Jean-Pierre Olié; Wally Landsberg; Patricia Dewaele; Robert D McQuade; Jean-Yves Loze; Delphine Hennicken; Wendy Kerselaers
Journal:  Int J Neuropsychopharmacol       Date:  2010-05-12       Impact factor: 5.176

2.  Clinical practice guidelines. Treatment of schizophrenia.

Authors: 
Journal:  Can J Psychiatry       Date:  2005-11       Impact factor: 4.356

3.  Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Authors:  Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

4.  Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

Authors:  G Bondolfi; H Dufour; M Patris; J P May; U Billeter; C B Eap; P Baumann
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

5.  Clozapine alone versus clozapine and risperidone with refractory schizophrenia.

Authors:  William G Honer; Allen E Thornton; Eric Y H Chen; Raymond C K Chan; Jessica O Y Wong; Andrea Bergmann; Peter Falkai; Edith Pomarol-Clotet; Peter J McKenna; Emmanuel Stip; Richard Williams; G William MacEwan; Kishor Wasan; Ric Procyshyn
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

6.  Risperidone in treatment-refractory schizophrenia.

Authors:  D A Wirshing; B D Marshall; M F Green; J Mintz; S R Marder; W C Wirshing
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

7.  Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.

Authors:  Richard C Josiassen; Ashok Joseph; Eva Kohegyi; Sudhir Stokes; Mahmood Dadvand; Wynn Wynn Paing; Rita A Shaughnessy
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

8.  Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.

Authors:  G D Tollefson; M A Birkett; G M Kiesler; A J Wood
Journal:  Biol Psychiatry       Date:  2001-01-01       Impact factor: 13.382

9.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.

Authors:  A Claus; J Bollen; H De Cuyper; M Eneman; M Malfroid; J Peuskens; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1992-04       Impact factor: 6.392

10.  Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Authors:  Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Leslie Citrome; Brian Sheitman; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112
View more
  7 in total

Review 1.  Wendan decoction (温胆汤) for treatment of schizophrenia: a systematic review of randomized controlled trials.

Authors:  Yi-wen Che; Ke-yu Yao; Yu-peng Xi; Zi-jie Chen; Yong-le Li; Ning Yu; Shuang-qing Zhai
Journal:  Chin J Integr Med       Date:  2015-04-06       Impact factor: 1.978

Review 2.  Antipsychotic combinations for schizophrenia.

Authors:  Javier Ortiz-Orendain; Santiago Castiello-de Obeso; Luis Enrique Colunga-Lozano; Yue Hu; Nicola Maayan; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

3.  Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort.

Authors:  Caroline Hynes; Stephen McWilliams; Mark Clarke; Ita Fitzgerald; Larkin Feeney; Mark Taylor; Fiona Boland; Dolores Keating
Journal:  Ther Adv Psychopharmacol       Date:  2020-09-25

4.  Optimization of Antipsychotic and Benzodiazepine Drugs in Patients with Severe Mental Disorders in an Intensive Case Management Program.

Authors:  María-José Alvarez; Pere Roura-Poch; Nùria Riera; Ana Martín; Clara Blanch; Judit Pons; Josep-Manel Santos; Santiago Escoté
Journal:  Community Ment Health J       Date:  2018-10-23

Review 5.  Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.

Authors:  Sharea Ijaz; Blanca Bolea; Simon Davies; Jelena Savović; Alison Richards; Sarah Sullivan; Paul Moran
Journal:  BMC Psychiatry       Date:  2018-09-03       Impact factor: 3.630

Review 6.  Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.

Authors:  Sang Won Jeon; Yong-Ku Kim
Journal:  Int J Mol Sci       Date:  2017-10-18       Impact factor: 5.923

7.  Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.

Authors:  Wondim Ayenew; Getahun Asmamaw; Teshome Bitew
Journal:  Int J Neuropsychopharmacol       Date:  2021-12-08       Impact factor: 5.176
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.